Opioid Addiction Treatment in Atlanta, Georgia
Opioid use disorder is the deadliest substance use challenge in metro Atlanta and across Georgia. The opioid crisis has evolved through three distinct waves — prescription opioid overprescribing beginning in the late 1990s, a shift to heroin as prescribing restrictions tightened in the 2010s, and the current wave driven by illicitly manufactured fentanyl. In Fulton County, opioid overdoses increased by 110 percent between 2019 and 2021. Nationally, overdose deaths decreased 27 percent in 2024, offering the first significant signal of improvement — but effective treatment remains essential. Inpatient opioid treatment in Atlanta combines medically supervised detox with medication-assisted treatment (MAT) and behavioral therapy, all covered by PPO insurance under federal parity law.
What is the best treatment for opioid addiction?
The most effective treatment for opioid addiction is medication-assisted treatment (MAT) combined with behavioral therapy in a structured residential setting. MAT uses FDA-approved medications — buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) — to stabilize brain chemistry, reduce cravings, and prevent withdrawal symptoms. Research published in the New England Journal of Medicine and endorsed by the American Society of Addiction Medicine (ASAM) consistently shows that MAT reduces overdose mortality by 50 percent or more compared to abstinence-only approaches. The behavioral therapy component — typically cognitive behavioral therapy (CBT), motivational interviewing, and contingency management — addresses the psychological and behavioral patterns that drive opioid use. In Atlanta-area inpatient programs, MAT is initiated during the detox phase and continued through residential treatment, with plans for long-term maintenance after discharge. This integrated approach produces the strongest outcomes for sustained recovery.
What is the new treatment for opioid addiction?
Several newer treatment approaches for opioid addiction have emerged. Sublocade — a monthly injectable form of buprenorphine — eliminates the need for daily medication and reduces the risk of diversion or missed doses. Extended-release naltrexone (Vivitrol) provides 30 days of opioid-blocking effects from a single injection. Lofexidine (Lucemyra) is the first non-opioid medication FDA-approved specifically for managing opioid withdrawal symptoms. In the research pipeline, opioid vaccines designed to produce antibodies that neutralize opioids before they reach the brain are in clinical trials. Neuromodulation techniques including transcranial magnetic stimulation (TMS) are being studied for their ability to reduce cravings. In clinical practice, the most impactful development is the expansion of buprenorphine prescribing — the elimination of the X-waiver requirement in 2023 means more physicians can prescribe buprenorphine, improving access to MAT during and after inpatient treatment.
What is the timeline for opioid withdrawal?
Opioid withdrawal follows a timeline that depends on the specific opioid used. For short-acting opioids like heroin and fentanyl, withdrawal begins 8 to 12 hours after the last dose, peaks at 36 to 72 hours, and resolves in 7 to 10 days. For longer-acting opioids like oxycodone and hydrocodone, withdrawal may not begin for 12 to 24 hours and peaks at 48 to 72 hours. For methadone and other long-acting formulations, withdrawal onset may be delayed 24 to 48 hours with symptoms lasting 14 to 21 days. Regardless of the opioid, the withdrawal syndrome includes similar symptoms: early-stage muscle aches, anxiety, insomnia, and sweating; peak-stage nausea, vomiting, diarrhea, abdominal cramping, and goosebumps; and a post-acute phase of persistent insomnia, irritability, and cravings that can last weeks to months. Medically supervised detox in an inpatient setting manages withdrawal with buprenorphine induction, clonidine, and symptom-specific medications.
What medications are used to treat opioid addiction?
Three FDA-approved medications are the foundation of opioid addiction treatment. Buprenorphine (available as Suboxone, Subutex, Zubsolv, and injectable Sublocade) is a partial opioid agonist that activates opioid receptors enough to reduce cravings and prevent withdrawal without producing the euphoria of full agonists. It is the most commonly used MAT medication in inpatient rehab settings because it can be initiated during active withdrawal. Methadone is a full opioid agonist administered daily in specialized clinics — it is the longest-established MAT medication with decades of research supporting its effectiveness for severe opioid use disorder. Naltrexone (available as oral Revia or monthly injectable Vivitrol) is an opioid antagonist that completely blocks opioid receptors — it is used after detox is complete and requires 7 to 14 days of opioid abstinence before initiation. The choice among these medications depends on the severity of opioid use disorder, patient preference, and the treatment setting.
What is the 72 hour rule for opioids?
The 72-hour rule in the context of opioid treatment refers to the federal regulation that allows physicians to administer (but not prescribe) opioid agonist medications like buprenorphine for up to 72 hours to treat acute withdrawal in an emergency setting, without the patient being enrolled in a formal opioid treatment program. This rule facilitates bridge treatment — providing immediate withdrawal relief while arranging admission to an inpatient program or formal MAT program. In practice, this means that an individual experiencing opioid withdrawal can receive buprenorphine in a hospital emergency department or urgent care setting to stabilize their condition while the admissions team at an inpatient facility completes the insurance verification and intake process. This 72-hour window is often the critical bridge between a crisis moment and entry into comprehensive treatment.
Ready to Start Treatment?
Our placement specialists verify your PPO insurance in 15 minutes and walk you through every option — no pressure, no obligation.
Frequently Asked Questions
How much does opioid treatment cost?
Opioid treatment costs vary by setting. Inpatient rehab ranges from $10,000 to $30,000 for 30 days before insurance is applied. With PPO insurance, out-of-pocket costs are typically $2,000 to $8,000. Ongoing MAT with buprenorphine costs $200 to $500 per month before insurance is applied, often covered by PPO plans at low copays. The cost of treatment is significantly less than the financial impact of continued opioid use.
What is the success rate of opioid recovery?
Research shows that medication-assisted treatment (MAT) for opioid addiction reduces overdose deaths by 50 percent or more. Treatment retention rates — a key predictor of long-term recovery — are 60 to 80 percent with MAT compared to 20 to 30 percent with abstinence-only approaches. Longer treatment stays and continued MAT after discharge produce the strongest outcomes.
What are the worst days of opioid withdrawal?
The worst days of opioid withdrawal are typically days 2 and 3 (36 to 72 hours after the last dose) for short-acting opioids like heroin and fentanyl. During this peak, symptoms include severe nausea, vomiting, diarrhea, muscle cramping, and intense cravings. Medically supervised detox significantly reduces the severity of these peak symptoms through medication management.
Do people go to rehab for suboxone?
Some individuals enter rehab specifically to transition off buprenorphine (Suboxone) under medical supervision. However, current clinical guidelines from ASAM recommend continuing MAT for as long as clinically appropriate — it is not a second addiction but a medical treatment for a chronic condition. The decision to taper should be made with medical guidance, not forced by stigma.